Cargando…
Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma
Considering that Aurora kinase inhibitors are currently under clinical investigation in hematologic cancers, the identification of molecular events that limit the response to such agents is essential for enhancing clinical outcomes. Here, we discover a NF-κB-inducing kinase (NIK)-c-Abl-STAT3 signali...
Autores principales: | Mazzera, Laura, Abeltino, Manuela, Lombardi, Guerino, Cantoni, Anna Maria, Ria, Roberto, Ricca, Micaela, Saltarella, Ilaria, Naponelli, Valeria, Rizzi, Federica Maria Angela, Perris, Roberto, Corradi, Attilio, Vacca, Angelo, Bonati, Antonio, Lunghi, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959191/ https://www.ncbi.nlm.nih.gov/pubmed/30948493 http://dx.doi.org/10.3324/haematol.2018.208280 |
Ejemplares similares
-
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia
por: Mazzera, Laura, et al.
Publicado: (2023) -
Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
por: Illert, Anna L., et al.
Publicado: (2014) -
Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2018) -
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
por: Okabe, Seiichi, et al.
Publicado: (2013) -
Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review
por: Gavriilidis, Paschalis, et al.
Publicado: (2015)